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Abstract
Background: Three studies have previously reported data that were interpreted by the authors
as supportive of association between schizophrenia and polymorphisms in the gene encoding the
metabotropic glutamate receptor GRM3.
Methods: In a bid to examine this hypothesis, we examined seven SNPs spanning GRM3 in a UK
case-control sample (schizophrenic cases n = 674, controls n = 716). These included all SNPs
previously reported to be associated, alone or in haplotypes, with schizophrenia in European or
European American samples.
Results: Our data showed no evidence for association with single markers, or 2, 3, 4 and 5 marker
haplotypes, nor did any specific haplotypes show evidence for association according to previously
observed patterns.
Conclusion: Examination of our own data and those of other groups leads us to conclude that at
present,  GRM3  should not be viewed as a gene for which there is replicated evidence for
association with schizophrenia.
Background
Glutamate is the major excitatory neurotransmitter in the
central nervous system (CNS) where its effects are medi-
ated through a diverse group of ionotropic receptors [N-
methyl D-aspartate receptors (NMDA), alpha-amino-3-
hydroxy-5-methyl-4-isoxazole propionate receptors
(AMPA), kainate (KA) and delta] and eight metabotropic
receptor isoforms. Abnormal glutamatergic transmission
has been proposed in schizophrenia, initially from the
observation that exposure to NMDA receptor antagonists
such as phencyclidine (PCP) can cause symptoms of
schizophrenia [1,2] and also relapse in patients with
schizophrenia [3]. More recently, agonists of metabo-
tropic glutamate receptors 2 and 3 (GRM2 and GRM3)
have been shown to ameliorate the adverse behavioral
effects induced by phencyclidine in the mouse [4].
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The GRM3 gene (GRM3) is therefore an attractive candi-
date gene for schizophrenia and there have been several
reports of allelic association studies examining polymor-
phisms in this gene [5-8]. These findings, however, do not
provide compelling evidence for association. Marti et al.,
[5] screened the coding exons and flanking intronic
sequence of GRM3 for polymorphisms in 46 schizophren-
ics and 46 bipolar patients. Three variants were identified,
one of which (+1131C>T, from here on referred to as
rs2228595) revealed significant (p = 0.002) evidence for
association in a German sample of 265 schizophrenics
and 227 controls, a finding that did not replicate in the
same study either in a second case-control sample or in a
family-based association sample, each if which was also of
German origin [5]. The second study of this gene was
based upon low density linkage disequilibrium (LD) anal-
ysis in a Japanese population [6]. Of six SNPs examined,
one, rs1468412, was nominally significantly associated
with schizophrenia (p = 0.01). A number of 2 and 3
marker haplotype combinations also yielded support for
the association that was surprisingly strong (minimum
global p ~0.001) given the sample size was only 100
schizophrenic cases and 100 controls. In the third study
[7], rs2228595, which showed un-replicated evidence for
increased frequency of the T allele in the earlier German
study [5] showed a trend for association of the C allele, (p
= 0.08), in a sample of white European American siblings,
but not in a second sample of 67 white European Ameri-
can families with one or more affected offspring, or in the
two samples combined (616 transmissions observed, 612
expected). Analysis of a further 6 SNPs revealed nominally
significant evidence (p = 0.02, uncorrected) for associa-
tion between an intronic SNP (hcV11245618, from here
on referred to as rs6465084) in their first sample. This
finding did not replicate in the second Caucasian sample,
with any trend being towards excess transmission of the
opposite allele, nor in an African American sample of 51
families. The latter sample however yielded evidence for
association (p = 0.03) to the allele at rs1468412 that was
significantly under-represented in the earlier Japanese
study [6]. Haplotype analysis in their Caucasian sib sam-
ple revealed a number of related significant 3 and 5
marker haplotypes (minimum global p = 0.006) but no
replication data were presented and it is difficult to deter-
mine from the presented data to what extent these find-
ings could be expected by chance.
In the most recent study, 7 SNPs were examined in 752
Han Chinese cases and controls [8]. Of the SNPs previ-
ously reported to be associated, only rs1468412 was gen-
otyped in this study but this did not reveal evidence for
association. However, rs2299225 (which has not been
genotyped in any other published datasets) yielded nom-
inally significant evidence (p = 0.03, uncorrected) as did a
3 marker haplotype (global p = 0.0017). Examination of
the data suggest that the latter analysis essentially reflects
the association at the single locus (frequencies of
rs2299225 risk allele = 6.3% in cases, 4.5% in controls;
frequency of three marker risk haplotype in cases = 6.2%
in cases, 4% in controls), and the extra 'global' signifi-
cance may have resulted from the use of a statistical test
that does not allow for any error in estimating haplotype
frequencies.
The hypothesis that this gene may influence schizophre-
nia susceptibility has gained currency from the observa-
tion that homozygosity for one of the alleles of a SNP in
GRM3 is associated with certain aspects of cognition [7]
that have been proposed as intermediate phenotypes for
the disorder. Moreover, in that study, homozygosity of the
same SNP was also associated in vivo with lower indices of
synaptic neurotransmission and glutamatatergic function
as determined by neuroimaging, and also in post-mortem
brain by lower expression of the glial glutamate trans-
porter EAAT2.
Thus the genetic evidence in favour of GRM3 is at present
ambiguous. What is, however, abundantly clear from two
of the studies [6,7] is that it is necessary to invoke genetic
heterogeneity (of patterns of LD and/or of the susceptibil-
ity alleles per se) with respect to ethnicity if the existing
data are to be interpreted as supportive of GRM3 as a true
susceptibility gene for schizophrenia. Therefore in a bid to
attempt to provide support for GRM3 as a susceptibility
gene for schizophrenia, we have focussed on those poly-
morphisms and haplotypes that have provided significant
evidence in Caucasian samples. We typed the SNP show-
ing significance in one of the original German samples [5]
as well as the SNPs reported by Egan and colleagues [7],
in a large UK based case control sample of 674 cases and
716 controls.
Methods
Subjects
All case-control subjects used in this study were unrelated
Caucasians born in the UK or Ireland. All cases met DSM-
IV criteria for schizophrenia. Consensus diagnoses were
made by two raters from all available information follow-
ing a semi-structured interview, SCAN or PSE [9,10], and
examination of case notes. The cases consisted of 456
males and 218 females, average age at collection 44.5
years ± 14.6, whilst the controls consisted of 482 males
and 234 females, average age at collection 41.5 years ±
11.5 years. Control individuals were group matched to
cases for age, sex, and ethnicity from more than 1400
blood donors recruited from the National Blood Transfu-
sion Service. Individuals on medication are not allowed to
donate blood in the UK nor are they remunerated even for
expenses. Thus unlike in some countries, donating blood
in the UK is entirely an altruistic process that does notBMC Psychiatry 2005, 5:23 http://www.biomedcentral.com/1471-244X/5/23
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tend to enrich for indigents, or people with substance
abuses or psychosis. Donors were not screened for the
absence of psychiatric illness, as this does not affect the
power when a disease has the population prevalence of
schizophrenia [11]. Multicentre and Local Research Ethics
Committee approval was obtained, and all subjects, both
cases and controls, gave written informed consent to
participate.
Genotyping
All SNPs were genotyped using the Sequenom MassAR-
RAY™ system as per the manufacturer's instructions. Assay
design and PCR conditions are available on request. All
assays were optimised initially by genotyping DNA from
30 CEPH parent-offspring trios from 21 families (Utah
residents with ancestry from northern and western
Europe), as detailed in the international hapmap project
[12]. 46 of these DNA samples were re-genotyped along
with the case-control sample to provide a measure of gen-
otyping accuracy. All genotypes were called blind to sam-
ple identity and affected status.
Statistical analysis
All p values are two tailed. Tests of genotypic and allelic
association were performed using contingency tables.
Haplotype analyses were performed using the EM algo-
rithm and a permutation test as implemented in program
EH plus [13]. Linkage disequilibrium values were calcu-
lated using the ldmax program within the GOLD software
[14].
Results
Allele frequencies for all SNPs and haplotype frequencies
were similar to those reported previously in a Caucasian
sample [7]. All markers were in Hardy-Weinberg equilib-
rium in both cases and controls. Double genotyping of 46
CEPH DNAs for all markers gave 100% concordance (a
total of 312 genotypes). Genotype data were available
from the Hapmap database for rs917071 and rs1468412.
The genotypes we obtained for these individuals were
identical to those in the Hapmap database. No significant
differences, allelic or genotypic, were observed between
cases and controls for any marker even uncorrected for
multiple testing (table 1). The only finding approaching
nominal significance was for marker rs187993 which
yielded a genotypic p-value of 0.06 (2df). No 2, 3, 4 or 5
marker haplotypes yielded evidence for association (data
not shown), nor did any of the specific 3 and 5 marker
haplotypes reported as significant by Egan et al., [7] under
specific 1df tests (table 2).
Allele frequencies and linkage disequilibrium data for the
CEPH families were similar to those obtained for the cases
and the controls. The LD relationships between markers
are given in table 3.
Discussion
We sought to replicate specific findings of association
between GRM3 and schizophrenia in European and Euro-
pean-American samples using a large, UK based case-con-
trol sample. However, our data reveal no support for
association between any single markers or haplotypes that
would represent either replication or indeed novel find-
Table 1: GRM3 single marker data
n 11 12 22 p-value 1 2 p-value
rs187993 case 590 303 228 59 0.06 834 (0.71) 346 (0.29) 0.11
T/G control 637 287 288 62 862 (0.68) 412 (0.32)
rs13242038 case 660 431 213 16 0.19 1075 (0.81) 245 (0.19) 0.60
C/T control 703 460 214 29 1134 (0.81) 272 (0.19)
rs917071 case 659 337 272 50 0.61 946 (0.72) 372 (0.28) 0.33
C/T control 697 373 278 46 1024 (0.73) 370 (0.27)
rs6465084 case 666 375 246 45 0.93 996 (0.75) 336 (0.25) 0.73
A/G control 708 406 255 47 1067 (0.75) 349 (0.25)
rs2228595 case 663 561 98 4 0.85 1220 (0.92) 106 (0.08) 0.64
C/T control 705 602 100 3 1304 (0.92) 106 (0.08)
rs1468412 case 663 345 264 54 0.68 954 (0.72) 372 (0.28) 0.41
A/T control 698 375 274 49 1024 (0.73) 372 (0.27)
rs7804100 case 652 363 250 39 0.63 976 (0.75) 328 (0.25) 0.46
G/A control 704 401 269 34 1071 (0.76) 337 (0.24)
Genotype and allele counts are shown for each SNP. Allele frequencies are shown in brackets. Minor alleles are coded as 2, using coding strand 
format as per Egan et al., [6]. For comparison between studies, rs2228595 was identified by Marti et al., [8] as +1131C>T and is referred to as snp5 
in Egan et al., [6]. rs13242038, rs6465084 and rs7804100 are referred to as hCV2627921, hCV11245618 and hCV2536213 respectively in Egan et 
al., [6].BMC Psychiatry 2005, 5:23 http://www.biomedcentral.com/1471-244X/5/23
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ings of association. With respect to the specific markers of
interest from previous work, marker rs2228595 [5]
showed an almost identical allele frequency in cases and
controls, with a slight excess (less than 0.5%) of the minor
T allele in cases. Thus our data are congruent with the
overall combined data reported in the work of Marti and
colleagues [5] and also the follow up study of Egan and
colleagues [7], and do not support the hypothesis that this
allele is associated with schizophrenia. Like Egan and col-
leagues [7], and unsurprisingly given the postulated eth-
nic heterogeneity at this locus, we could also not replicate
the association between schizophrenia and rs1468412
previously reported in the Japanese sample [6]. However,
in contrast to the sibs sample of Egan and colleagues [7],
but similar to their family sample, we found a slight excess
(0.6%) of the major allele of rs6465084 in controls rather
than in cases. Our haplotype analyses were no more sup-
portive of the findings of Egan and colleagues than our
single locus analyses. The only specific haplotype reported
as associated in that study that approached significance in
our sample (nominal p = 0.09, 1df) was the 211 haplo-
type constructed from rs187993, rs13242038 and
rs917071. However, in contrast to the earlier work, we
found this to be more common in controls than cases.
There are numerous reasons why in the face of a true asso-
ciation in different samples, different markers and haplo-
types might be associated with a disease [15] and
therefore it should not in itself be a major concern that the
data concerning GRM3 follow such a pattern. However,
we should nevertheless remain vigilant to the onus in sci-
ence being rejection of the null hypothesis, and, in the
face of confusing patterns of association which may be
explicable by heterogeneity, should have explicit criteria
Table 2: GRM3 haplotype data
SNP Study Haplotype
rs187993 2
rs13242038 1 1 1
rs917071 1 1 1 1
r s 6 4 6 5 0 8 4 1111
rs1468412 111
rs7804100 11
Global P valuea Egan et al 2004 0.23 0.05 0.01 0.01 0.01
Cardiff 0.52 0.80 0.79 0.88 0.82
Best p value b Egan et al 2004 0.01 0.01 0.01 0.00 0.00
Cardiff 0.09 0.58 0.60 0.60 0.98
Frequencyc Egan et al 2004 0.29 0.57 0.62 0.61 0.53
Cardiff cases 0.29 0.62 0.66 0.64 0.58
Cardiff controls 0.32 0.63 0.67 0.65 0.58
Comparison of haplotypes for Cardiff case-control sample and Egan et al., [6] Caucasian sample. a global p-value, b best p-value in Egan et al., [6] 
compared with same haplotype in Cardiff sample, c Frequency of significant haplotype. In the Cardiff analysis, the no. of controls from 623 to 693 
and the no. of cases ranges from 582 to 652.
Table 3: GRM3 linkage disequilibrium data
rs187993 rs13242038 rs917071 rs6465084 rs2228595 rs1468412 rs7804100
rs187993 x 1 0.94 0.67 0.96 0.57 0.35
rs13242038 0.11 x 0.50 0.38 1 0.32 0.48
rs917071 0.16 0.16 x 0.78 0.91 0.71 0.46
rs6465084 0.07 0.10 0.54 x 0.96 0.86 0.45
rs2228595 0.04 0.18 0.18 0.23 x 0.97 0.60
rs1468412 0.57 0.32 0.50 0.66 0.21 x 0.69
rs7804100 0.35 0.16 0.18 0.20 0.01 0.41 x
LD data for case control sample. D' is shown above the diagonal and r2 is shown below the diagonal.BMC Psychiatry 2005, 5:23 http://www.biomedcentral.com/1471-244X/5/23
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for what constitutes replication. A commonsense
approach is that exact replication of an allele or haplotype
under conventional levels of significance (p < 0.05) can be
regarded as replication, with the proviso that if multiple
specific hypotheses are tested, this is allowed for. No two
studies of GRM3 meet this particular criterion for replica-
tion. In our own study, we anticipated that rs6465084
would be the most likely marker to replicate in our sam-
ple. Although only associated with affected status in one
of two Caucasian samples in the study of Egan and col-
leagues, [7] this marker independently showed evidence
for association with measures of glutamate transporter
gene expression in post-mortem samples and with neuro-
imaging based indices of functionality in controls. This
suggested to us that if the findings were not due to chance,
they might generalize beyond the specific group of cases
reported in that study. Unfortunately, our study provides
no support for that prediction.
Alternatively, in the presence of heterogeneity, any study
reporting association to novel markers or haplotypes can
be considered to provide significant replication provided
the analysis allows appropriately (which is not the same
as Bonferroni correction) for multiple testing. Given the
numbers of markers it is now possible to test in a gene,
failure to require this will inevitably lead to accumulation
of studies with nominally significant evidence in support
of certain markers or haplotypes. It is unclear that any two
of the above studies can be considered to provide convinc-
ing 'stand alone' evidence for association that would meet
this criterion; ours certainly does not. Thus even in the
absence of our own data, we do not concur with the sug-
gestion [16] that the evidence for GRM3 meets the criteria
for significant evidence for association proposed in a
meta-analysis of association studies with common vari-
ants [17]. However, we do concur with sentiments of
Lohmueller et al., [17] whose paper was published "in the
light of the seemingly high proportion of false positives in
the literature" and who urged the publication of large
studies and negative results.
While the current data concerning GRM3 do not allow
rejection of the null hypothesis, they are insufficient to
rule out the possibility of GRM3 as a true susceptibility
gene for schizophrenia. GRM3 spans 221 kb and across
this region, the level of linkage disequilibrium across
GRM3 is moderate (table 3). The current crop of data from
the Hapmap includes 63 informative SNPs of which only
28 are redundant using one of the commonly used meth-
ods [18]. Thus it does not appear that any of the previous
studies, including our own, extract a high proportion of
the genetic information relevant to GRM3. Whether the
existing data suggest that such a study is of sufficient pri-
ority to justify embarking upon what is still for most,
including ourselves, a costly and time consuming endeav-
our is clearly a matter for individual researchers. In our
view it does not. However, future replication attempts
would be greatly facilitated if this challenge were to be
taken up by one or more of the groups with data that they
themselves consider to be convincing.
Conclusion
In a bid to attempt to provide support for GRM3 as a sus-
ceptibility gene for schizophrenia, we have genotyped
those polymorphisms that have provided significant evi-
dence in Caucasian samples in a large UK based case con-
trol sample. Our data do not support the hypothesis that
variation in GRM3 is associated with schizophrenia. How-
ever, given the moderate level of linkage disequilibrium
across this gene, both this study and other current data are
insufficient to rule out the possibility that GRM3 is a true
susceptibility gene for schizophrenia. This will require
Schematic of GRM3 structure with locations of SNPs genotyped in this study Figure 1
Schematic of GRM3 structure with locations of SNPs genotyped in this study. Exons are represented as black boxes. Larger 
boxing represents coding sequence, and smaller represents UTR. Connecting black lines represent intronic sequence. 
rs2299225, (significant in Chen et al., [8]) maps to intron 3, but was not typed in this study.
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studies which extract a higher proportion of the genetic
data from GRM3.
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